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ABSTRACT

Background: Consumers are exposed to thousands of advertisements, most all of which are
designed to promote a particular brand and accompanying brand name. The selection of a
brand name is a critical strategic decision and is an important means to building brand equity.
The importance of branding elements, specifically brand names, has led pharmaceutical
manufacturers to become more creative and open the possibilities of language in brand name
development. Given the complexities associated with brand name development in the US
pharmaceutical industry and the trends observed in recent pharmaceutical brand names,
advancing the understanding of how brand name selection can affect patient judgments will
be beneficial and extend previous research findings to this distinct arena. When consumers or
patients see complex, often unfamiliar pharmaceutical brand names, the brand names alone
may convey certain feelings and negative judgments, potentially affecting multiple aspects of
the pharmacologic intervention. The purpose of this research was to explore the relationship
between pharmaceutical brand name fluency and subsequent patient judgments associated
with processing a pharmaceutical brand name.

Methods: A total of 100 study participants were selected from a patient panel who have selfreported rheumatoid arthritis. Study participants were assigned to one of two groups of
pharmaceutical brand names, fluent or disfluent and then exposed to the associated 10
pharmaceutical brand names. Participants were instructed to imagine they were reading the
pharmaceutical brand name as part of an advertisement for the product and asked to assess the
ii

perceived risk, familiarity, and willingness to request the pharmaceutical product from their
physician. A two-condition between-subject approach was used for testing statistical
significance of a single mediation model for the effects of fluency on perceived risk through
familiarity. A moderated serial mediator model was incorporated to assess the effects of
fluency and risk perception on willingness to request the product and to determine the
moderating role of disease severity on the relationship between perceived risk and willingness
to request.

Results: Results showed that participants exposed to fluent brand names did not consider the
products to be more familiar and there was no evidence that the fluency of the brand names
influenced the perceived risk of the product independent of the effects of fluency on
familiarity. Additionally, willingness to request the pharmaceutical product is not affected by
the perceived risk of the product regardless of the level of disease severity.
Conclusion: The current research is the first study to our knowledge that demonstrates
pharmaceutical brand name fluency does not affect perceived risk of the product or willingness
to request the medication in actual patients who are evaluating drug names indicated to treat
their condition or disease.
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LIST OF ABBREVIATIONS AND SYMBOLS
CEDR

Center for Drug Evaluation and Research

CPG

Consumer Packaged Goods

DDMAC

Division of Drug Marketing, Advertising, and Communications

DMEPA

Division of Medication Error Prevention and Analysis

FDA

Food and Drug Administration

OPDP

The Office of Prescription Drug Promotion

OSE

Office of Surveillance and Epidemiology

US

United States
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United States Adopted Names Council

VAS

Visual Analogue Scale
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CHAPTER I: INTRODUCTION

Traditional Brand Name Development
Research has indicated that on any given day, a person can be exposed to thousands of
advertisements, most all of which are designed to promote a particular brand and accompanying
brand name (Johnson 2006; Story 2007). Throughout many consumer product categories, brand
names come in a multitude of forms. Such brand names are designed with a specific target market
in mind, and the choice of the brand name is a critical strategic decision, requiring significant
consideration. No matter the origin of a brand name or market for which the product is targeted,
the choice of a brand name has been suggested as an important means to building brand equity
(Aaker 1991; Keller et al. 1998). This is paramount to a brand’s profitability and sustainability
because, in many of today’s fast-paced markets, it is difficult to maintain a competitive
advantage on performance attributes alone (Kohli and LaBahn 1997). Such market dynamics
require strong brand imagery to be established and leveraged.
Extant literature suggests brands with strong brand images can influence choice and
command a premium (Aaker 1991; Kohli and LaBahn 1997). The brand name is a fundamental
part of brand image and considered the anchor for brand positioning initiatives (Kohli and
LaBahn 1997). Recognizing the significance of a brand name, marketing research has proposed
various normative approaches to developing and selecting an effective brand name.
Keller et al. (1998 pg. 48) posited that selecting “inherently meaningful” brand names,
such that the name itself conveys relevant product information, is one strategic opportunity to
1

enhance brand name awareness and identification within a product category. The researchers also
prescribed a second strategy, which involves choosing a “suggestive” brand name (Keller et al.
1998 pg. 48). The suggestive approach to brand naming is considered to facilitate and assist with
positioning efforts. Additionally, Collins (1977) provided two basic naming strategies, which
were referred to as the “Juliet Principle” and the “Joyce Principle.” The first strategy, the “Juliet
Principle”, focuses on choosing a brand name and establishing the name in the consumers’ mind
through repetition (Kohli and LaBahn 1997). The second strategy, the “Joyce Principle”, involves
choosing a brand name that has the desirable phonetic symbolism for the product, which refers to
the non-arbitrary relationship between sound and meaning (Kohli and LaBahn 1997). Although
these examples and others within extant literature address many aspects of the brand naming
process for conventional consumer products and categories, little focus has been directed towards
the brand naming processes and implications of brand name selection within the pharmaceutical
industry.

Brand Name Development within the US Pharmaceutical Industry
An effective pharmaceutical brand name has been considered by many researchers and
marketing practitioners alike to play a critical role in building and maintaining customer loyalty
and accordingly, as a very important element in contributing to the value and wealth creation of a
pharmaceutical brand (Blackett and Robins 2001). Indeed, the brand name of a pharmaceutical
product is likely the one element that will remain constant throughout the product’s lifetime.
Because of this significance, many pharmaceutical manufactures spend considerable resources in
developing and selecting the ideal brand name for their products (Russell 2007). However, unlike
many consumer product categories, the development and choice of a pharmaceutical brand name
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in the Unites States (US) has significant regulations governing the process. Pharmaceutical
manufacturers do not have the same autonomy found within consumer-packaged goods (CPG)
markets for brand name selection and, therefore, are limited in their ability to use many of the
prescribed and aforementioned naming strategies found within the marketing literature.

Regulatory Environment for Pharmaceutical Brand Name Development
As US pharmaceutical manufacturers’ pipelines produce more diminished returns and
overcoming the increasing use of generic alternatives becomes onerous, strategic focus on the
development and management of a pharmaceutical brand becomes quite conspicuous. During the
1980s and 1990s, naming a drug within the US pharmaceutical marketplace was less complex
than today’s environment (Blackett and Robins 2001). Increases in the number of products
entering the market and increases in the regulatory requirements put forth by the US Food and
Drug Administration (FDA) regarding naming a pharmaceutical product have challenged
companies attempting to successfully differentiate their products through brand name
development.
In recent years, the FDA has focused on increasing the safe use of drug products by
minimizing user errors attributed to unclear nomenclature, labels, labeling and other packaging
aspects of pharmaceutical products. This is primarily due to the growth in medication errors that
has been realized throughout the US health system. Furthermore, as consumers become exposed
to more and more pharmaceutical advertisements and pharmaceutical brand names, the role of the
US FDA in reducing brand name confusion takes on an ever-growing importance (Fish and
Richardson 2010). Pharmaceutical manufacturers must ensure that the investment associated with
developing a brand name is not offset by failing to pass this FDA rigor of approving the name.

3

The Center for Drug Evaluation and Research (CDER) received approximately 126,000 reports
of medication errors from 2000 – 2009, many of which were considered to be directly related to
the similar sound and appearance of drug name pairs (FDA Guidance Document 2014).
Additionally, there are approximately 3 billion retail prescriptions adjudicated annually in the US.
Of these prescriptions, about 12.5% of medication errors are attributed to confusion by healthcare
practitioners between drug names (World Trademark Review 2016). Because of this trend,
CDER, a component of the US FDA, has developed and refined internal procedures for
evaluating the potential for a proposed brand names to cause or contribute to medication errors as
part of the Center’s focus on the safe use of drug and therapeutic biologic products (FDA
Guidance Document 2014).
The review of proposed pharmaceutical brand names is conducted by the Division of
Medication Error Prevention and Analysis (DMEPA) in CDER’s Office of Surveillance and
Epidemiology (OSE). The Office of Prescription Drug Promotion (OPDP), formerly the Division
of Drug Marketing, Advertising, and Communications (DDMAC), works in consultation with
DMEPA to determine the acceptability of proposed pharmaceutical brand names seeking
marketing approval. These regulatory agencies provide broad guidance to manufacturers, which,
if followed, will increase the likelihood of acceptance or approval of a proposed pharmaceutical
brand name.
Adding to the complexity associated with brand naming processes in the US
pharmaceutical industry, pharmaceutical manufacturers must also be cognizant of the generic
name of the pharmaceutical product, which differs from the brand name or trade name. In the US,
the generic name of the pharmaceutical product is a by-product of the USAN, which stands for
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the United States Adopted Name. The USAN is obtained through collaboration with the United
States Adopted Names Council (USANC), which serves the health profession in the US by
selecting simple, informative, and unique nonproprietary names (i.e. “stems”) for drugs by
establishing logical nomenclature classifications based on pharmacological and chemical
relationships (AMA 2016). A pharmaceutical manufacturer is responsible for applying and
receiving approval for a USAN (typically completed in Phase II) before the brand name can be
filed with the FDA. Although the generic name is not always translated directly into the
pharmaceutical brand name, many products have traces of the generic name or ‘stem’ in the
brand name. One famous example of this naming strategy exist with the product Lipitor, which
combines a portion of the word “lipid” with a portion of the stem “-tor” from the generic name
(atorvastatin).

Brand Naming Trends within the US Pharmaceutical Industry
It becomes apparent that within the US pharmaceutical industry, manufacturers are
wedged between the tried-and-true brand naming strategies that extant marketing literature
prescribes and the stringent boundaries that are imposed by regulatory bodies responsible for
approving pharmaceutical brand names. Due to these peculiar market conditions, one is left to
wonder just how pharmaceutical brand names are actually created and how these names are
perceived by prescribers and patients. Although there are a host of opinions and difficult to
decipher meanings in pharmaceutical brand name development, there has been little consensus
among firms in approach. Trends in pharmaceutical brand names have been noted among choices
that make use of linguistic tricks such as plosive letters ‘P’, ‘T’, and ‘D’ in an effort to convey
power (Ipaktchian 2005). Other trends have been observed with the use of fricative letters such as
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‘X’, ‘F’, ‘Z’, and ‘S’ to imply speed (Ipaktchian 2005). This, in part, helps explain the number of
Xs and Zs that have been present within drug names in recent years.
The importance of branding elements, specifically brand names, has led pharmaceutical
manufacturers to become more creative and open the possibilities of language in brand name
development. More classic vowel/consonant constructions have ceded to more “innovative”
approaches, such as the conjunction of consonants seen with products like Vfend and Qvar
(Blackett and Robbins 2001). Such unnatural brand names may seem “strategic” at first glance
but could end up being problematic in more ways than imagined. Many of the new generation
drug names can be hard to spell and more importantly hard to pronounce.
Given the complexities associated with brand name development in the US
pharmaceutical industry and the trends observed in recent pharmaceutical brand names,
advancing the understanding of how brand name selection can affect patient judgments will be
beneficial and extend previous research findings to this distinct arena. That is, when consumers or
patients see complex, often unfamiliar pharmaceutical brand names, the brand names alone may
convey certain feelings and negative judgments. Such judgments and perceptions of
pharmaceutical products inferred through the brand name could potentially affect multiple
aspects of the pharmacologic intervention, to include treatment choice, willingness to inquire
about the medication, primary adherence, and other important and associated outcomes. If
evidence supports that such feelings are indeed associated with certain pharmaceutical brand
names, this could prove to be harmful to advertisement initiatives that are intended to promote
patient and physician dialogue. Patients may shy away from asking about or discussing a
potentially beneficial pharmaceutical product with their healthcare provider simply because of
the brand name. Furthermore, these unintended consequences of pharmaceutical brand name
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judgments could easily be avoided by considering the risk perceptions of consumers and patients
in brand name development initiatives.

Study Aims
The broad purpose of this research is to explore the relationship between pharmaceutical
brand name fluency and subsequent patient judgments associated with processing a
pharmaceutical brand name. To achieve these broad objectives, the study had the following aims:

1. To evaluate the perceived risk associated with a pharmaceutical product based on the
pharmaceutical brand name fluency.

2. To investigate whether the effects of linguistic fluency on perceived risk is mediated by
patients’ perceived familiarity of the pharmaceutical brand name.

3. To assess the effects of linguistic fluency and risk perception associated with
pharmaceutical brand name fluency on a patient’s willingness to request a pharmaceutical
product.

4. To assess whether disease severity moderates the relationship between perceived risk and
patients’ willingness to request a pharmaceutical product.
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CHAPTER II: REVIEW OF LITERATURE AND CONCEPTUAL FRAMEWORK

Processing Fluency
Human judgment reflects not only the content of our thoughts but also the metacognitive
experience of processing the thoughts (Alter and Oppenheimer 2009). Many theories involving
consumer judgments make the assumption that peoples’ judgments are formed based on
informational aspects that are pertinent to the target and serendipitously come to mind at the time
of evaluation (Schwarz 2004). If this were indeed the case, consumers would ideally assess a
product more favorably when more positive attributes of the product come to mind. Similarly,
from a normative perspective, consumers should evaluate the validity of a product claim by
drawing on relevant accessible knowledge about the respective content domain (Schwarz 2004).
Based on this rationale, a pharmaceutical product which includes the most superior efficacy and
safety data, would surely “win” in the minds of patients when direct-to-consumer advertising is
conducted. Empirical evidence does not support this proposition and research surrounding
metacognitive experiences in consumer judgment and decision-making provides some
explanation into this matter.
Consumers’ thought processes are guided by metacognitive experiences, such as the ease
or difficulty with which the information presented can be brought to mind or the fluency with
which new information can be processed (Schwarz 2004). Because of this, research has
demonstrated that an individual’s judgment often departs from what one would predict based on
the accessible declarative information (Schwarz 2004). Schwarz (2004) posited that such findings
8

show that the subjective experiences that accompany the thought process qualify the implications
of accessible declarative information, sometimes to the extent that the judgment is paradoxical to
what the accessible content would suggest.
Schwarz (2004) concluded that based on an individual’s metacognitive experiences, the
person’s conclusion depends on their naïve theories of memory and cognition. In other words, an
evaluation is based on an individual’s assumption about just how easy or difficult the stimulant
causes one to think of certain things or to process new information. This assertion is intriguing
and relevant to the development of pharmaceutical brand names, especially at it relates to
consumers who are intrinsically less informed and knowledgeable about the specific utility and
clinical attributes of drug therapies. The issue becomes more concerning when considering the
increasing level of exposure that many consumers have to drug names and advertisements.
Additional research regarding the effects of processing fluency may help shed light on this issue.
Lee (2004) extended the work by Schwarz (2004) and proposed that the metacognitive
route to judgment could occur more often that Schwarz first suggested. More specifically, Lee
(2004) refined Schwarz’s examination regarding the effects of processing fluency on judgments
of liking and preference by making salient the distinction between how individuals process a
target and how individuals process information about the target.
Schwarz (2004) posited that an individual’s metacognitive experience may be the basis for
judgments of truth, but the individual’s positive experience of processing fluency actually drives
judgments of preference (Lee 2004; Schwarz 2004). In other words, Lee (2004) hypothesized that
an individual’s attitude toward a target (e.g. the brand) will become more favorable when the
target is perceptually fluent. In a thorough review of the literature surrounding this topic, Lee
(2004) concluded that judgments often depend on how easy it is for an individual to process the
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target rather than information about the target at the time of evaluation. In addition to the work by
both Lee (2004) and Schwarz (2004) regarding processing fluency, other research has argued that
processing fluency is one component of fluency but other forms of fluency should also be
considered when addressing the effects of subjective feelings or ease of fluency.

Additional Forms of Fluency
Researchers have addressed the broad construct of fluency in various manners since
Schwarz (1990) showed that fluency influences judgment independently of the retrieved content
that accompanies the experience of fluency. Alter and Oppenheimer (2009) summarized the idea
of fluency by positing that every cognitive task can be described along a continuum from
effortless to highly effortful, which produces a corresponding metacognitive experience that
ranges from fluent to disfluent. The researchers went on to further categorize the various
byproducts or forms of fluency including perception, memory, embodied cognition, linguistic
processing, and higher order cognition (Alter and Oppenheimer 2009). Using this classification
(Figure 1), it is the specific aspects of linguistic processing that are of interest as it relates to the
effects of pharmaceutical brand names on patient perceptions.
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Figure 1: Classification of Various Instantiations of Fluency
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The Components of Linguistic Processing and Effects on Fluency
One area of linguistic fluency that has been addressed by prior research and will be further
examined within this research is phonological fluency. Simply put, certain letter strings are easier
to process than others (Alter and Oppenheimer 2009). Phonological fluency helps explain why
the difficulty, or lack thereof, in pronouncing certain names engenders the experience of
disfluency. Research has indicated that English speakers struggle to pronounce certain names and
obscure words and that these experiences translate into intriguing judgments (Alter and
Oppenheimer 2009).
Alter and Oppenheimer (2006) investigated the impact of phonological fluency on the
ability to predict short-term stock share fluctuations. In coordination with prior research findings,
Alter and Oppenheimer (2006) hypothesized that when people attempt to understand complicated
information, they often simplify the task by relying on mental shortcuts, or heuristics. In other
words, the researchers wanted to analyze whether people tend to judge stimuli that were fluent, or
in this case easy to pronounce, more positively on a range of evaluative dimensions (Alter and
Oppenheimer 2006). By manipulating phonological fluency through the complexities of
fabricated stock and company names, or how easy the names were to pronounce, the researchers
were able to demonstrate that people prefer to invest in stocks and the companies with fluent
rather than disfluent names (Alter and Oppenheimer 2006). Additionally, the researchers sought
to support these findings by analyzing actual market data based on the ease of pronunciation of
ticker codes as a predictor of actual stock performance (Alter and Oppenheimer 2006). The
findings aligned with prior studies and showed that shares with pronounceable ticker codes
outperformed those with unpronounceable ticker codes.
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With similar research aims in mind, Laham et al. (2012) addressed phonologic fluency by
investigating what the researchers coined as the name-pronunciation effect. This phenomenon is
essentially synonymous with the construct of phonologic fluency that other research has
addressed but differs slightly by levering the hedonic marking hypothesis (Winkielman et al.
2003). Simply put, the researchers posited that experiencing a name activates a rich set of
semantic information, which impacts impression formation and evaluation (Laham et al. 2012).
Throughout a series of experiments in a range of laboratory settings, the researchers demonstrated
the name-pronunciation effect and found that easy- to-pronounce names are evaluated more
positively than difficult-to-pronounce names. This effect was even realized in one experiment by
demonstrating that subjects rated one potential candidate running for office as more suitable than
another, with all information presented held constant except for the ease of pronunciation of the
candidate’s name (Laham et al. 2012). One of the most important takeaways from this research
and one that is not addressed in similar research is that the researchers were able to demonstrate
the robustness of fluency effects, even in potentially information-rich contexts. This is relevant
to the current research in that consumers often have access to other information in addition to the
pharmaceutical brand name. Some may argue that because consumers often make judgments
about a pharmaceutical product in an information-rich environment, the brand name and
associated linguistic fluency may contribute little to impression formation. The work by Laham
et al. (2012) was able to demonstrate that the name pronunciation impacts liking and other
evaluative measures strongly and consistently, even when other cues are accessible.
A considerable amount of research has evaluated phonologic fluency associated with
names and found that people tend to prefer easy to pronounce names over difficult to pronounce
names (Song and Schwarz 2009; Alter and Oppenheimer 2006, 2009). After reviewing social
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psychology and consumer behavior literature, these relationships may seem intuitive. However,
one may ask why does this phenomenon matter and how does it relate to brand naming trends
among pharmaceutical products? An inspection of additional research regarding fluency and
perceived risk helps to connect the dots.

Effects of Fluency on Familiarity and Perceived Risk
Since the initial introduction to the marketing literature of the concept of perceived risk,
many researchers have focused on levering the ideas of risk and risk reduction (Bauer 1960;
Bettman 1973). Perceived risk has been defined as the expectations of losses associated with a
decision or purchase (Ganther and Kreling 1999). The concept of loss can be a monetary loss or a
non-monetary loss. Bettman (1973) posited that there are two main components to perceived risk:
the chance component, which refers to the probability of a loss, and the severity component.
It has also been demonstrated that people respond differently to the hazards that they
perceive (Slovic et al. 1981). Some perceived hazards are accompanied with extensive objective
evaluative inputs while others may be based on direct experience. Despite some instances of
objectivity, all forms of risk assessment are considered to include a large component of subjective
judgment (Slovic et al. 1981). Accordingly, consumers are often asked to evaluate risks in
situations where they seldom have in-depth evidence on hand to support their judgments. In these
types of positions, extant literature has identified a number of general inferential rules that people
use (Slovic et al. 1981). These rules are referred to as heuristics and are used to reduce difficult
mental task to simpler ones or mental shortcuts (Slovic et al. 1981). This particularly important
implication directly relates to the perceived risks people may deduce, which can be affected by
processing fluency.
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Slovic et al. (2004) addressed the affective components of risk, which is the specific
quality of goodness or badness experienced as a feeling of state, with or without consciousness.
The researchers posited that affective responses occur rapidly and automatically and that the
reliance of such feelings could be characterized as “the affect heuristic” (Slovic et al. 2004).
Affect plays an important role in what literature suggests as the dual-process theories of thinking,
knowing, and information processing (Chaiken and Trope 1999; Kahneman and Fredrick 2002;
Sloman 1996; Slovic et al. 2004). These two routes are referred to as the experiential and analytic
systems.
One of the main characteristics of the experiential system is its affective basis (Slovic et
al. 2004). Zajonc (1984) posited that affective reactions to stimuli are often the first reactions to
stimuli, occurring automatically and subsequently guiding information processing and judgment.
Even though analysis is important in some decision-making situations, reliance on affect and
emotions is quicker, easier, and more efficient. Studies indicate that even though risk and benefit
tend to be positively correlated in the world, they are negatively correlated in people’s minds
(Slovic et al. 2004; Fischhoff et al. 1978). In other words, people base their judgments of an
activity or technology not only on what they think but also on how they feel about it (Alhakami
and Slovic 1994; Slovic et al. 2004). These findings are important for the current research such
that if consumer feelings toward processing a brand name are favorable, then they may likely be
moved toward judging the risks as low and the benefits as high.
Song and Schwarz (2009) sought to extend prior research surrounding risk perception
(Lowenstein et al. 2001), which conceptualized ordinary risk judgment as one that is an intuitive
rather than analytic process, involving the role of feelings such as like, fear, and anxiety in risk
perception. The researchers did so by exploring how fluency contributes to the concept of “risk as
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feelings” (Slovic et al. 2004; Song and Schwarz 2009). Extant literature has demonstrated that
information that is fluent is perceived as more familiar and therefore evokes a more positive
affective response than disfluent information (Schwarz 2004). The logic behind these findings is
that because familiar material is easier to process than novel material, consumers infer familiarity
from ease of processing (Pocheptsova et al. 2010; Song and Schwarz 2009). It has been
demonstrated that in general, consumers will attribute the metacognitive difficulty experiences
when processing information or thinking about an advertised product to unfamiliarity with the
product (Pocheptsova et al. 2010).
Researchers believe that the positive impact of metacognitive ease of processing on
evaluative judgments is due to a perceived connection between ease and familiarity or between
difficulty and unfamiliarity (Song and Schwarz 2009).
Accordingly, Song and Schwarz (2009) hypothesized that if apparent familiarity does
indeed play a prominent role in intuitive judgments of risk, then novel information or stimuli
should be perceived as less risky when the information is easy rather than difficult to process. By
using ease of pronunciation to manipulate processing fluency, Song and Schwarz (2009)
demonstrated that people perceive disfluently processed stimuli as riskier than fluently processed
stimuli. The findings for this research extend prior work by suggesting that fluency
manipulations, and specifically ease of pronunciation, may shed light on management of
perceived risk (Song and Schwarz 2009). In other words, disfluent product names may infer risk,
erroneously or not, to a consumer simply based on the ease of pronunciation of the brand name.

Phonetic Effects and Heuristic Cues of Brand Names

16

Literature indicates that a specific component of linguistic fluency is phonological fluency
(Alter and Oppenheimer 2009). The relevant aspect to phonological fluency in regard to the goals
of this research stems from the belief that phonetic symbolism, or the relation between sound and
meaning (Lowrey and Shrum 2007), conveys certain cues to a person. The idea that the mere
sound of a word, apart from the actual definition, has itself meaning and is important to brand
name selection. Such sounds are derived from phonemes, which are the smallest units of a sound
(i.e. the sound of an individual letter). Sound symbolism has been recognized as an important
factor in how a person infers specific meaning from a brand that is considered as unfamiliar
(Yorkston and Menon 2004). Although marketing researchers might have been aware of the
presence of sound qualities in names, the work by Klink (2000, 2001, 2003) first applied the
principles of phonology to marketing research. Klink investigated the idea that different vowels
and consonants are articulated in different areas of the mouth (e.g. front of mouth or back of
mouth) and that such front/back articulation affects consumers’ perceptions of the quality of the
sound in a name, thereby inducing inferred attributes in the brand name of a product.
In building upon the work by Klink (2000, 2001, 2003), Yorkston and Menon (2004)
hypothesized that if a brand name contains phonemes that represent attributes a consumer desires,
then the consumer will hold more positive attitudes and exhibit higher purchase intentions toward
that brand. The researchers were able to demonstrate through two different experiments,
manipulating a single vowel sound in a brand name, the process by which sound symbolism
manifests in consumer judgments and that the process is incontrollable, outside of awareness, and
effortless, therefore making it automatic (Yorkston and Menon 2004). Furthermore, this research
seems to indicate that sound symbolism, although evaluated on the attribute level, affects overall
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evaluations.
Additional research has indicated that certain sounds seem to be consistently related to
concepts such as disgust or dislike in the English language (Jespersen 2013; Lowrey and Shrum
2007). If this is indeed occurring in the minds of consumers, then brand names that contain these
sounds might also be regarded as negative (Lowrey and Shrum 2007).
Indeed, Smith (1998) demonstrated this logic through an experiment using names of candidates
containing vowel sounds that are used to express disgust and candidate names that might be less
favorably perceived. By constructing a “comfort index” surrounding phonetics and analyzing US
presidential election outcomes, beginning in 1824 through 1992, he found that the candidate with
the highest comfort index won the popular vote in 35,

or 83%, of the elections (Smith 1998).

He then extended this analysis to local elections, US Senate and House elections and found
overwhelming evidence that favorably named candidates won a majority of elections over less
favorably named candidates (Smith 1998).

The Effects of Fluency within the Pharmaceutical Marketplace
Although research assessing the effects of brand name fluency within the pharmaceutical
marketplace is limited, recent research has emerged which helps to demonstrate the impact of
pharmaceutical brand names on consumers’ evaluations and behavioral intentions. Dohle and
Siegrist (2013) examined the impact of a pharmaceutical’s brand name on evaluations and
behavioral intentions, appealing to the representativeness heuristic and fluency theory. In a series
of experiments on a student population with hypothetical scenarios, the researchers demonstrated
that participants judged pharmaceutical products with simple names as safer and were more
willing to buy the products. Additional research by Tasso, Gavarzzi, and Lotto (2014)
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investigated whether drug names affect judgments surrounding efficacy, risk, and other properties
associated with the products. In a series of experiments, the researchers found evidence to support
the notion that the name of a drug may involve a promise, influencing the perceived power of the
product and that this psychological power is conveyed through persuasive drug names (Tasso,
Gavarzzi, and Lotto 2014). Cho (2014) extended the work by Dohle and Siegrist (2013) by
exploring the malleability of the name fluency effect on pharmaceutical drug perception by
examining the fluency effect in the domain of risk versus advancedness judgment. In an
experiment among students, the researchers were able to demonstrate that the simplicity or
complexity of a drug name can affect patient perceptions, evaluations, and potentially
medication-use behaviors. Finally, Dohle and Montoya examined the effects of processing
fluency for pharmaceutical brand names on dosing behavior (Dohle and Montoya 2017). In two
experiments among university students and survey panel participants in Europe, the researchers
demonstrated that fluent drug names resulted in lower dosage of drugs compared to disfluent
names (Dohle and Montoya 2017). However, their experiments did not find support for the
previously presented evidence for the mediating role of familiarity to the fluency-risk relationship
(Dohle and Montoya 2017).
Aligned with the increasing body of research surrounding the effects of fluency, with
specific focus aimed at the unique aspects of the US pharmaceutical industry, the aim of this
research was to assess the effects of pharmaceutical brand name fluency on familiarity and
perceived risk. More specifically, and as demonstrated by Song and Schwarz (2009), this study
assesses the effects of linguistic fluency associated with pharmaceutical brand names on a
patients’ perceived risk of the product. Furthermore, this study addresses the role of familiarity as
a possible mediating variable to this relationship.
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The Effects of Disease Severity on Patient Acceptance of Perceived Risk
It is apparent from the prior discussion surrounding various effects of fluency that both lay
consumers and patients may derive certain judgments about a pharmaceutical product simply
based on the brand name. This is an important component to this research; however, it is also
important to consider the effects of disease severity on patients’ judgments. Most pharmaceutical
products are accompanied by both the possibility of therapeutic or desirable effects and the
possibility of adverse events or undesirable effects. Because of this, healthcare providers often
attempt to use the attitudes of patients regarding the risks and benefits of a drug as one factor in
their choice of therapy (Eraker and Sox 1981). From the patient’s perspective, perceived risk and
their willingness to proceed down a particular treatment path may be influenced by the severity
of their condition. Much of this cognitive process may be explained through adaptation theory
and the hedonic treadmill theory.
Brickman and Campbell (1971) described the hedonic treadmill as a process similar to
sensory adaptation with people’s emotional reactions to life events (Diener, Lucas, and Scollon
2006). The researchers posited that one’s emotion system adjusts to one’s current life
circumstances and that all reactions are relative to one’s prior experience (Brickman and
Campbell 1971; Diner, Lucas, and Scollon 2006). This was characterized in the work by
Brickman, Coates, and Janoff-Bulman (1978) when the researchers showed empirical support for
the treadmill model. They concluded that lottery winners were not happier than non-winners and
that people with paraplegia were not substantially less happy than those who could walk
(Brickman, Coates, and Janoff-Bulman 1978; Diner, Lucas, and Scollon 2006). Relevant to this
research, the idea of hedonic adaptation aids in understanding how different patients may have
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conflicting responses to the perceived risks associated with a particular pharmaceutical product
based on their state of well-being and the severity of their disease.
In following this logic, Johnson et al. (2009) assessed whether adult patients are more
tolerant of treatment risks than parents of juvenile patients and found that adult patients and
parents of juvenile patients with Crohn’s disease (CD) were willing to accept similar levels of
severe adverse event risk. The authors posited that these findings might be explained by
adaptation theory (Johnson et al. 2009). In their position for using adaptation theory to explain
this finding, the researchers explained that patients with less serious cases have to imagine what it
would be like to have more serious symptoms and that because patients with more severe cases
often learn to adapt over time, more serious symptoms may not be as detrimental to quality of life
as the less sever patients imagine (Johnson et al. 2009). In fact, Johnson et al. (2007) found that
patients with more severe CD are actually less tolerant of severe adverse event risk than patients
with less severe CD. The researchers also found that patients whose symptoms had little or no
effect on their activities of daily living were willing to take more risks compared with patients
who reported considerable problems in daily activities (Johnson et al. 2007).
Other research surrounding patients’ assessments towards and willingness to take risks
associated with pharmaceutical products has demonstrated conflicting evidence to these findings.
For example, Lacy et al. (2012) explored patients’ risk-taking behavior and their willingness to
take medication risks in irritable bowel syndrome (IBS). The researchers found that IBS patients
with severe symptoms were more willing to take significant medication risks that those with mild
or moderate symptoms, which is in direct contrast to the studies within CD (Lacy et al. 2012).
Specific to rheumatoid arthritis, research has indicated a pattern of reluctance in arthritis patients
to accept the risk of drug-related adverse effects. Fraenkel et al. (2001) found that in general,
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rheumatoid arthritis patients are very concerned about potential drug toxicity. The researchers
demonstrated that risk adversity appeared to be attenuated by a patient’s past experience with
adverse events and that patients with milder disease activity may be more hesitant to accept
commonly used medications if they are aware of potential adverse events (Fraenkel et al. 2001).
Throughout multiple conditions and across various types of pharmacologic options, the
literature demonstrates mixed findings in the extent and direction to which disease severity can
affect patients’ judgments and willingness to pursue a treatment option. This may in part be due
to the nature of the symptoms associated with a condition as some symptoms become more
apparent than others. Addressing these individual differences among various conditions is outside
the scope of this current research. However, it is clear that the disease severity of a patient can
indeed affect the perceived risks and willingness to pursue a pharmaceutical intervention.
Because of this, it is considered relevant and necessary to include disease severity as a
component to the assessing the effects of fluency on judgments with a specific patient population
and accordingly, will be included in this current proposal.

The Effects of Fluency and Perceived Risks on Patient Medication Requests
Although direct-to-consumer advertisements (DTCA) for branded pharmaceutical
products are a marketing tactic, designed to increase market share of a particular product over a
competitive alternative, a potentially positive effect of advertisements lies in the idea that the ads
may encourage patients to visit their healthcare providers to inquire about the medical condition
and therapeutic options for treatment (Sinkinson and Starc 2015). This marketing channel
addresses the changes in patient behavior, such that in recent decades, patients have become more
active participants in their medical care (McKinlay et al. 2014). In fact, since the FDA began
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allowing DTCA in 1997, research has indicated that approximately 30% of Americans talk with
their doctor about a medicine they saw advertised, of whom approximately 44% report that their
doctor prescribed the medication requested (Berger et al. 2001; McKinlay et al. 2014).
Active requests from patient to provider regarding specific medications have been
demonstrated to significantly affect prescribing behavior. For example, in a study by McKinlay
and colleagues, one in five physicians reported that they would prescribe oxycodone to patients
requesting the drug (for sciatica patients) compared to only 1% of physicians who viewed the
same clinical scenario with a patient who made a passive request for pain relief (McKinlay et al.
2014).

General Study Purpose
As demonstrated in previous research and findings from a review of the literature, brand
names are considered to be a critical component to establishing a brand’s equity and competitive
advantage in the marketplace. Because of the significance of brand names in a product’s
marketing effectiveness, extant literature has proposed various normative approaches to
constructing brand names. Although such strategies may be leveraged in many consumer product
categories, pharmaceutical manufacturers do not have the autonomy to employ such prescribed
brand naming methods. Because of the intricacies within the pharmaceutical market, there has
been little consensus regarding effective brand naming strategies among pharmaceutical
manufacturers, resulting in a variety of pharmaceutical brand naming tactics, considered by many
to be complicated and difficult to pronounce brand names.
Given the complexities associated with pharmaceutical brand names, advancing
understanding of how brand name selection may affect patient judgments and calls to action will
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be beneficial to the healthcare community and pharmaceutical manufacturers, while also
extending previous findings to this important field. Thus, the general focus of this research is to
understand the relationship between the fluency associated with pharmaceutical brand manes and
patient perceptions and judgments that are experienced while processing the brand names.

Specific Aims and Hypotheses
In order to meet the specific aims previously listed, the study sought to test the following
sets of hypotheses based on the literature:

Aim 1: Evaluate the perceived risk associated with a pharmaceutical product based on the
pharmaceutical brand name fluency.
H1a: There is a statistically significant relationship between the linguistic fluency of individual
pharmaceutical brand names and patients’ perceived risk of the pharmaceutical product.

Aim 2: Investigate whether the effects of linguistic fluency on perceived risk is mediated by
patients’ perceived familiarity of the pharmaceutical brand name.

H2a: The relationship between linguistic fluency of the pharmaceutical brand names and perceived
risk is mediated by familiarity.

Aim 3: Assess the effects of fluency and risk perceptions on willingness to request
H3a: There is a statistically significant relationship between linguistic fluency and a patient’s
perceived risk of a pharmaceutical product and the patients’ willingness to request a
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pharmaceutical product.

Aim 4: Assess whether disease severity moderates the relationship between perceived risk
and patients’ willingness to request a pharmaceutical product
H4a: Disease severity moderates the relationship between the perceived risk of a pharmaceutical
product and willingness to request the pharmaceutical product.
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CHAPTER III: METHODS
Using a non-scientific website (Wordlab Drug-O-Matic Name Generator 2016), 45
randomly generated, fictitious pharmaceutical brand names were developed. The pharmaceutical
brand names differed in length, consonant and vowel frequencies, and beginning letter selection.
The goal of the process was to develop a thorough list of names that could be tested in a pre-test
setting with consumers and then subsequently used in the experiment with patients. The purpose
of creating fictitious names was to use the pharmaceutical brand names to measure the various
effects of fluency on patient judgments, without bias to prior exposures or experiences with
branded pharmaceutical products.

Measuring the Construct of Fluency
As previously discussed, the broad construct of fluency can refer to virtually any cognitive
task described along a continuum from effortless to highly effortful, which then produces a
corresponding metacognitive experience that can be described along a continuum from fluent to
disfluent (Alter and Oppenheimer 2009). For the purposes of this research, fluency was defined as
the ease of pronunciation of the fictitious pharmaceutical brand names.
Accordingly, an ease of pronunciation measure was incorporated as a proxy measure for the
construct of linguistic fluency.

Pre-test
Having established the 45 fictitious pharmaceutical brand names, pre-testing the names for
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ease of pronunciation was conducted. A pre-test survey was fielded using Amazon's Mechanical
Turk (MTurk). Participants followed a link to the survey. Briefing instructions were provided and
participants were asked to rate the ease of pronunciation of the 45 pharmaceutical brand names.
Pre-test participants were asked to rate the ease of pronunciation of the pharmaceutical brand
name products individually using the 7-point response scale. Fluency was measured by having
participants rate the ease of pronunciation of the fictitious pharmaceutical brand products. This
measure was captured using a single- item interval response scale ranging from 1 = very difficult
to pronounce, 7 = easy to pronounce with each scale value between poles labeled (appendix A).
Once the ratings for all 45 products were obtained, the pharmaceutical brand names were
categorized based on the level of fluency ratings. This provided two groups of 10 pharmaceutical
brand names based on fluency ratings that were used to manipulate fluency in the forthcoming
experiment: one group of easy-to-pronounce names and one group of difficult-to-pronounce
names.
In order to assess that the two groups of names were statistically different from one
another, a t-test was conducted to compare the easy to pronounce group with the difficult to
pronounce group. The a priori significance level (alpha) was set at 0.05. Although participation
in the pretest was voluntary, an Institutional Review Board (IRB) application was obtained
before commencement of the pretest and subsequent research.

Sample Selection
A total of 100 study participants were selected from a patient panel maintained by L&E
Research. The patient panel is voluntary and comprises approximately 1,000 patients who have
self-reported rheumatoid arthritis (RA). Payments to patients are provided for individual study

27

participation only and not for membership on the panel. Study participants were required to be 18
years of age or older, have a self-reported diagnosis of RA, and speak English. The selection
criteria and online survey link were provided to L&E Research with a target sample of 100
participants.

Procedure
Using the 20 pharmaceutical brand names (10 easy to pronounce and 10 difficult to
pronounce) determined as a result of the pre-test, study participants were assigned to one of two
groups of pharmaceutical brand names, fluent or disfluent. Participants in each group were then
exposed to the associated 10 pharmaceutical brand names, with order of the pharmaceutical brand
names presented randomly. Similar to the procedures used for the pre-test, briefing instructions
were provided at the beginning of the survey and participants were asked if they understood
everything, and were ready to begin the procedure. At the end of the experiment, participants
were provided debriefing information.
Since the participants in the study were not asked to rate the level of fluency associated
with the pharmaceutical brand names as part of the main experiment, it was important to ensure
fluency was indeed being manipulated. Accordingly, a manipulation check for the independent
variable of fluency for the pharmaceutical brand names was included at the end of each survey
for both groups. To conduct the manipulation check, participants from each group rated the
fluency for each of the ten associated pharmaceutical brand names. The fluency ratings for fluent
and disfluent groups were compared to data from the pre-test subjects to ensure the perceptions
of fluency were not statistically different. A directional t- test was performed comparing pre-test
mean ratings for both fluent and disfluent name ratings.
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Perceived Risk

Participants were instructed to imagine they were reading the pharmaceutical brand name
as part of an advertisement for the product and asked to assess the perceived risk they believe was
associated with the pharmaceutical product based solely on the brand name. Perceived risk was
conceptualized as physical risk. More specifically, participants were asked to rate the level of
concern they would have about using the product based on the brand name (Stone and Gronhaug
1993). The measure was captured on a 7-point scale ranging from 1 = very harmful, 7 = very
safe.

Familiarity
In addition to rating the perceived risk the participants associated to the pharmaceutical
brand name, participants were also asked to rate the perceived familiarity of the products based
on the pharmaceutical brand name. To capture the construct of familiarity, a proxy measure of
perceived novelty of the product was assessed using a single item interval response scale ranging
from 1 = very old, 7 = very new. The brand name of the pharmaceutical products was the only
stimuli presented (appendix C).

Disease Severity
Disease severity is hypothesized as moderating the relationship between perceived risk
and willingness to request a pharmaceutical product. In order to capture the moderating variable
of disease severity, a portion of the Health Assessment Questionnaire Disability Index (HAQ-DI)
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was administered. Two visual-analog scale (VAS) items within the HAQ-DI to assess pain and
health were incorporated as a global assessment of disease severity. Participants were asked to
indicate how much pain they had because of their RA in the past week on a scale of 0 to 100,
where zero represents “no pain” and 100 represents “severe pain”. Participants were also asked to
consider all of the ways their arthritis affects them on a scale of 0 to 100, where zero represents
“very well” and 100 represents “very poor” health. The two VAS items were summed to form the
measure of disease severity for each participant.

Willingness to Request
The participants’ willingness to request the pharmaceutical products served as the
dependent variable in the study. The goal of this measure was to investigate the effects of
fluency, perceived risk, and disease severity on a patient’s willingness to request the product to
which they have been exposed to in a promotional channel.
Similar measures of willingness regarding the use of pharmaceutical products have been
assessed in extant literature. For example, Peters and colleagues (2014) investigated various
formats for presenting medication risk information as it relates to a patient’s willingness to take
the drug. In their study, willingness was measured on a 7-point scale with 0 = not likely, 6 = very
likely. For the purpose of this study, the construct of willingness to request a pharmaceutical
product was measured using a 7-point scale ranging from 1 = very unlikely, 7 = very likely.
The hypothesized relationships among these variables and statistical designations are presented in
Figure 2 and Figure 3. Data were analyzed using the PROCESS macro in SPSS v23 (Hayes
2013).
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Figure 2:

Conceptual and Statistical Diagram of Single Mediator Model for Effects of
Fluency on Familiarity and Perceived Risk

Illustration of the direct effect of fluency on perceived risk
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Analysis
The data analysis plan for the first two specified aims of the study is discussed below.

Aim 1. Evaluate the perceived risk associated with a pharmaceutical brand name based on
the pharmaceutical brand name fluency.
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Aim 2. Investigate whether the effects of pharmaceutical brand name fluency on perceived
risk is mediated by familiarity.

To address the first two aims of the study and test the corresponding hypotheses, a twocondition between-subject approach was used for testing statistical significance of the single
mediation model. Using the two-condition between-subject design, three linear equations were
used to estimate the components of the hypothesized single-mediator model (MacKinnon 2008;
Montoya and Hayes 2015). The first step was to regress perceived risk
(Y) on pharmaceutical brand name fluency (X) and is used to assess the main effect of fluency on
perceived risk (equation 1).
Y = 1 + cX + 1

(1)

Consistent with the single mediation model presented in Figure 2, Y represents the
dependent variable of perceived risk, X represents the independent variable of pharmaceutical
brand name fluency, c represents the relationship between pharmaceutical brand name fluency
and perceived risk, 1 represents the intercepts, and 1 is the unexplained or error variance
(MacKinnon 2008). This equation defines the total effect model and c, the parameter estimate,
represents the effect of fluency on perceived risk.
Even if the relationship between these two variables is found to be statistically significant,
a mediated effect may still be present. Following the recommendations by MacKinnon (2008),
the following two regression equations are then analyzed and assessed for mediation:
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Y = 2 + c’X + bM + 2

(2)

M = 3 + aX +3

(3)

Consistent with the model presented in Figure 2, c’ represents the strength of prediction of
perceived risk from fluency, with the strength of the relationship between familiarity and
perceived risk removed (MacKinnon 2008; MacKinnon and Fairchild 2010). Next, the notation b
represents the coefficient for the strength of the relationship between familiarity and perceived
risk with the strength of the relationship between fluency and perceived risk removed. Finally,
the notation of a represents the coefficient for the strength of the relationship between fluency and
familiarity. The intercepts for each equation, representing the average score for each variable are
represented by 1-3 and the error terms are represented by 1-3 (MacKinnon 2008; MacKinnon
and Fairchild 2009).
To evaluate the hypothesized mediation effect, the bootstrap resampling method was used
(Bollen and Stine 1992; Efron 1992,1988; MacKinnon 2008). This statistical approach to
estimating and testing mediation effects has been shown to perform better than the Baron and
Kenny (1986) approach in small sample size studies (20-80) such as this study (Zhang and Wang
2007).
The bootstrapping method has no distributional assumption on the indirect effect of ab
from Figure 2. Instead, this method approximates the distribution using its bootstrap distribution
(Zhang and Wang 2007). Using the original data set as a population, a bootstrap sample of N
subjects with paired Y, X, and M randomly with replacement from the original data set was
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obtained. Next, from this bootstrap sample, estimates of ab (a_b_ ) through the OLS method were
obtained based on the second and third equation previously listed. Both c and c’ from Figure 2
are parameters relating fluency to perceived risk, but c’ is a partial effect, adjusted for the effects
of familiarity (MacKinnon 2008). The estimate of the mediated effect is considered equal to ĉ –c.’.
Repeating these first two steps, the empirical distribution of a_b_ based on the bootstrap
procedure can be viewed as the distribution of ab. Then (1-) x 100% confidence interval of ab
can be constructed using the (/2) x 100% and (1-/2) x 100% of the empirical distribution.
Accordingly, if mediation effects have occurred, the indirect effect ab should be significantly
different from zero (Zhang and Wang 2007; MacKinnon 2008).

34

CHAPTER IV: RESULTS

The data analysis plan for the remaining two specified aims of the study is discussed
below.

Aim 3. Assess the effects of linguistic fluency and risk perception associated with
pharmaceutical brand name fluency on a patient’s willingness to request the product.

Aim 4. Assess whether disease severity moderates the relationship between perceived risk
and patients’ willingness to request a pharmaceutical product

To address the third and fourth aim of the study and test the statistical significance of the
moderated serial mediator model, the statistical model is represented with the following three
equations:

M1 = iM1 + a1X + eM1

(4)

M2 = iM2 + a2X + d1M1 + eM2

(5) Y = iy + c1’X + b1M1 + b2M2

+ c2M2W + eY

(6)
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The serial mediator model has three specific indirect effects and one direct effect (Hayes
2013). One pathway is indirect and runs from fluency to willingness to request through
familiarity only. A second indirect path runs from fluency to willingness to request through
perceived risk only. A third indirect influence passes through both familiarity and perceived risk
sequentially, with familiarity affecting perceived risk (Hayes 2013). The remaining effect of
fluency is direct to willingness to request without passing through either familiarity or perceived
risk (Hayes 2013).
The three indirect effects are estimated as the product of regression weights linking fluency
to willingness to request through at least one mediator, familiarity or perceived risk (Hayes 2013).
The specific indirect effect of fluency on willingness to request through familiarity only is
represented as a1b1, the specific indirect effect through perceived risk only is represented as a2b2,
and the specific indirect effect through both familiarity and perceived risk in serial is a1d21b2.
(Hayes 2013). Combining these three indirect effects sum to the total indirect effect of fluency,
represented as a1b1 + a2b2 + a1d21b2 (Hayes 2013). When the total indirect effect of fluency is
added to the direct effect of fluency, the result is c, which is the total effect of fluency, and can be
estimated from the following regression equation:

c = c’ + a1b1 + a2b2 + a1d11b2

(7)

The total indirect effect of fluency on willingness to request in the serial mediator model
is the difference between the total effect of fluency on willingness to request and the direct effect
of fluency on willingness to request, as represented by the following equation:
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c - c’ = a1b1 + a2b2 + a1d11b2

(8)

Similar to the bootstrapping procedure described previously, bootstrap confidence
intervals for indirect effects were calculated repeatedly resampling from the data with
replacement, estimating the model in each bootstrap sample, calculating the indirect effects
described, and deriving endpoints of confidence intervals for each (Hayes 2013). An indirect
effect can be determined different from zero when the confidence interval does not contain zero
(Hayes 2013).
An analysis of the manipulation check indicated that the ten disfluent drug names were
considered more difficult to pronounce compared to the ten fluent drug names (t = 5.612,
p<0.001). Rankings for each of the ten drug names for both fluent and disfluent groups are
provided in table 1.
Table 1:

Fluency Ratings for Pharmaceutical Brand Names

Fluent Group
Drug Name

Mean Fluency
Rating

Disfluent Group
Std. Dev.

Drug Name

Mean Fluency
Rating

Std. Dev.

Velcin

6.07

1.181

Quthutix

2.65

1.780

Trivete

5.48

1.346

Niyxob

2.83

1.579

Naxalon

5.46

1.486

Oxgnue

3.21

1.864

Altorex

5.43

1.455

Vetlixfi

3.50

1.924

Cutrino

4.98

1.832

Asbixat

3.54

1.890

Runfina

4.63

1.743

Enyvfo

3.65

1.940

Vithoria

4.57

1.940

Subridke

3.69

1.858

Solotho

4.43

1.747

Qxibinle

3.75

1.707

Evafir

4.39

1.612

Docilge

4.17

1.730

Solatu

4.13

1.655

Oxtieze

4.23

1.574

Interval response scale ranging from 1 = very difficult to pronounce, 7 = easy to pronounce

A total of 94 participants with a self-reported diagnosis of rheumatoid arthritis completed the
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study (94% response rate). Participants averaged 52 years in age, with most being female (82%)
and Caucasian (65%). Of the 94 participants who completed the study, 95% were native English
speaking, and no participant indicated that they worked in a healthcare related field or for a
healthcare organization. More than half of the participants (57%) reporting taking four or more
prescription medications, and 82% indicated taking at least one prescription medication
specifically for their rheumatoid arthritis. An overview of study participant demographics and
sample characteristics is provided in table 2.
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Table 2: Study Participant Demographics and Sample Characteristics
Demographic Characteristic

Total

Fluent names

Disfluent names

52.7 (29-71)

53.2 (29-69)

52.3 (31-71)

Male

17 (18%)

7 (15%)

10 (21%)

Female

77 (82%)

39 (85%)

38 (79%)

White

61 (65%)

32 (70%)

29 (60%)

Hispanic or Latino

9 (10%)

3 (7%)

6 (13%)

Black or African American

21 (22%)

11 (24%)

10 (21%)

0 (0%)

0 (0%)

0 (0%)

Asian/Pacific Islander

1 (1%)

0 (0%)

1 (2%)

Other

2 (2%)

0 (0%)

2 (4%)

Yes

89 (95%)

44 (96%)

45 (94%)

No

5 (5%)

2 (4%)

3 (6%)

High school or diploma equivalent (e.g., GED)

25 (27%)

7 (15%)

18 (38%)

Associate degree

33 (35%)

17 (37%)

16 (33%)

Bachelor’s degree

28 (30%)

17 (37%)

11 (23%)

Master’s degree

7 (7%)

4 (9%)

3 (6%)

Professional degree

1 (1%)

1 (2%)

0 (0%)

Doctorate degree

0 (0%)

0 (0%)

0 (0%)

Yes

0 (0%)

0 (0%)

0 (0%)

No

94 (100%)

46 (100%)

48 (100%)

None

5 (5%)

1 (2%)

4 (8%)

1-3 prescriptions

36 (38%)

23 (50%)

13 (27%)

4-6 prescriptions

30 (32%)

12 (26%)

18 (38%)

More than 6 prescriptions

23 (25%)

10 (22%)

13 (27%)

None

17 (18%)

9 (20%)

8 (17%)

1

32 (34%)

17 (37%)

15 (31%)

2

28 (30%)

15 (33%)

13 (27%)

3 or more

17 (18%)

5 (11%)

12 (25%)

Injected or infused

9 (10%)

6 (13%)

3 (6%)

Oral

40 (43%)

19 (41%)

21 (44%)

28 (30%)

12 (26%)

16 (33%)

0 (0%)

(0%)

(0%)

Pain score*

51.50*

42.00*

61.00*

Health score*

40.00*

30.50*

50.00*

Age, years
Sex

Ethnicity

Native American or American Indian

Native English (US) speaker

Highest degree or level of school

Work in healthcare related field

Total number of prescriptions

Number of RA prescriptions

Type of RA medication

Both injected or infused and oral
Not sure

Disease severity

*Median VAS score
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The first and second hypotheses stated that there is a statistically significant relationship between
the fluency of individual pharmaceutical brand names and patients’ perceived risk of the
pharmaceutical product and that the relationship between linguistic fluency of pharmaceutical
brand names and perceived risk is mediated by familiarity. As indicated in Table 3, results from a
single mediation analysis showed that participants exposed to fluent brand names did not
consider the products to be more familiar (a = 2.604, p = 0.237); however, participants who
considered the brand names to be familiar did consider perceived risk to be lower (b = 0.221, p =
0.006). A bias-corrected bootstrap confidence interval for the indirect effect (ab = 0.575) based
on 10,000 bootstrap samples was not found to be significant (-0.239, 1.808). Furthermore, there
was no evidence that the fluency of the brand names influenced the perceived risk of the product
independent of the effects of fluency on familiarity (c’ = 1.293, p = 0.434).

Table 3:

Regression Coefficients, Standard Errors, and Model Summary for
Single Mediation Model for Effects of Brand Name Fluency on Perceived
Risk

Familiarity (M)
Variable

Fluency (X)

a

Familiarity (M)
Constant

Coeff.

SE

2.604

2.187

--i1

16.00

Perceived Risk (Y)
P

SE

P

0.237

c’

1.293

1.644

0.434

---

b

0.221

0.078

0.006

<.001

i2

36.618

1.705

<.001

---

1.563

Coeff.

R2 = 0.015

R2 = 0.093

F (1,92) = 1.4185, p = 0.237

F (2,91) = 4.689, p = 0.012
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Figure 4:

Statistical Diagram of Single Mediation Model for Effects of Brand
Name Fluency on Perceived Risk

eM
Familiarity

b = .221

a = 2.604

eY

Fluency

Perceived Risk
c’ = 1.293

Next, a serial mediation model with a second-stage moderating variable was analyzed to
assess the third and fourth hypotheses. The estimated regression coefficients from the serial
mediation model are presented in Table 4. Brand name fluency did not affect familiarity of the
product (a1 = 2.604, p = 0.237) or the perceived risk of the product (a2 = 1.293, p = 0.434). Like
findings from the single mediation analysis, perceived risk of the pharmaceutical product is
associated with the familiarity of the brand name (d1 = 0.221, p = 0.006); however, willingness
to request the pharmaceutical product is not affected by the perceived risk of the product (b2 =
0.364, p = 0.423), regardless of the level of disease severity (b3 = 0.003, p = 0.382).
The first indirect effect assessing the indirect effect of brand name fluency on willingness
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to request the product through familiarity, estimated as a1b1, was not found to be significant
(a1b1 = 0.336, -0.336, 1.452). The second indirect effect assessing the effect of brand name
fluency on willingness to request the product through both familiarity and perceived risk,
estimated as a1d1b2, was also found to not be significant (a1d1b2 = 0.209, -0.463, 1.084).
Finally, the third indirect effect of brand name fluency on willingness to request the product
through perceived risk, estimated as a2b2 was found to not be significant (a2b2 = 0.471, - 0.829,
3.611). The total indirect effect estimating the sum of all three indirect effects was determined to
not be different from zero (1.017, -0.795, 4.908).
Using PROCESS (Hayes 2013), all possible pairwise comparisons between the three
specified indirect effects are calculated to inform inference about differences between the specific
indirect effects. The confidence intervals for the three contrasts ([C1 = -0.837, 1.359], [C2 = 3.288, 1.639], and [C3 = -3.156, 1.218]) include zero and are not statistically different from each
other.
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Regression Coefficients, Standard Errors, and Model Summary for Serial Mediation Model for Effects of
Brand Name Fluency on Willingness to Request

Familiarity (M1)
Coeff.
Fluency (X)

a1

2.604

Familiarity
(M1)

Perceived Risk (M2)

95% CI
-1.738, 6.947

---

Coeff.
a2

---

1.293
d1

0.221

95% CI
-1.972, 4.559

---

---

---

---

Disease
Severity (W)

---

---

---

---

M2 x W

---

---

---

---

16.000

12.897, 19.103

iM1

R2 = 0.15

F (1,92) = 1.4185, p = 0.237

iM2

36.618

Coeff.
c’

0.066, 0.375

Perceived Risk
(M2)

Constant

Willingness to Request (Y)

33.230, 40.005

R2 = 0.093
F (2,91) = 4.689, p = 0.012

1.158
b1

b2

0.129
0.364
---

b3
iY

0.003
18.695

95% CI
-3.966, 6.281
-0.125, 0.383
-0.535, 1.253
---0.004, 0.010
-18.159, 55.549

R2 = 0.274
F (5,88) = 6.632, p = <0.001
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Table 4:

Figure 5:

Statistical Diagram of Serial Mediation Model
for Effects of Brand Name Fluency on
Willingness to Request

em1

em2

d1 = 0.221

Perceived Risk

Familiarity

Disease
b3 = 0.003
Severity

a

b1 = 0
129

1

=
2
.
6
0
4

a2 = 1.293

ey

b2 = 0.364

c’ = 1.158

Fluency

WTR

Sensitivity analyses
Following formal testing of the four study hypotheses, sensitivity analyses were conducted
to assess sensitivity of key study measures across varied settings. First, the original single
mediation model assessing the relationship between fluency of individual pharmaceutical brand
names and patients’ perceived risk of the pharmaceutical product and whether the relationship
between linguistic fluency of pharmaceutical brand names and perceived risk is mediated by
familiarity was analyzed. The difference in the sensitivity analyses and the original hypothesis
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testing for the first two study hypotheses included three different settings for the study measures.
In the first sensitivity analysis, perceived novelty instead of familiarity was analyzed to
determine if novelty mediated the relationship between pharmaceutical brand name fluency and
perceived risk. As can be seen in table 5, results from a single mediation analysis showed that
participants exposed to fluent brand names did not consider the products to be more novel (a =
3.788, p = 0.099) and novelty did not influence perceived risk (b = 0.150, p = 0.052). A biascorrected bootstrap confidence interval for the indirect effect (ab = 0.568) based on 10,000
bootstrap samples was not found to be significant (-0.01, 2.066). Furthermore, there was no
evidence that the fluency of the brand names influenced the perceived risk of the product
independent of the effects of fluency on familiarity (c’ = 1.300, p = 0.445).

Table 5:

Regression Coefficients, Standard Errors, and Model Summary for
Single Mediation Model for Effects of Brand Name Fluency on Perceived
Risk (Sensitivity Analysis with Novelty as Mediator)

Novelty (M)
Variable

Fluency (X)

a

Novelty (M)
Constant

Coeff.

SE

3.788

2.276

--i1

45.587

Perceived Risk (Y)
P

SE

P

0.099

c’

1.299

1.692

0.445

---

b

0.150

0.076

0.052

i2

33.299

3.680

<0.001

--1.626

Coeff.

<0.001

R2 = 0.029

R2 = 0.053

F (1,92) = 2.771, p = 0.099

F (2,91) = 2.566, p = 0.082

In the second post-hoc analysis, the three study variables included in the single mediation
analysis were only assessed based on the first pharmaceutical brand name presented to the
participant, as opposed to each participate evaluating all ten brand names within the randomized
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group assignment. As seen in table 6, results from a single mediation analysis using responses
from the first brand name presented only showed that the participants exposed to the first fluent
brand name only did not consider the products to be more familiar (a = 0.157, p = 0.379) and
familiarity was not associated with the perceived risk of the product (b = 0.244, p = 0.064). A
bias-corrected bootstrap confidence interval for the indirect effect (ab = 0.38) based on 10,000
bootstrap samples was not found to be significant (-0.029, 0.193). Furthermore, there was no
evidence that the fluency of the brand names influenced the perceived risk of the product
independent of the effects of fluency on familiarity (c’ = -0.025, p = 0.912).

Table 6:

Regression Coefficients, Standard Errors, and Model Summary for
Single Mediation Model for Effects of Brand Name Fluency on Perceived
Risk (Sensitivity Analysis with First Name)
Familiarity (M)

Variable

Fluency (X)

a

Familiarity (M)
Constant

i1

Perceived Risk (Y)

Coeff.

SE

P

0.157

0.177

0.379

c’

-0.025

0.221

0.912

---

---

---

b

0.244

0.130

0.064

1.239

0.127

i2

3.872

0.225

<0.001

<0.001

Coeff.

SE

P

R2 = 0.008

R2 = 0.037

F (1,92) = 0.782, p = 0.379

F (2,91) = 1.764, p = 0.177

Finally, in the third sensitivity analysis, the three study variables included in the single
mediation analysis were only assessed based on the either the most fluent or disfluent
pharmaceutical brand name presented to the participant, as opposed to each participate evaluating
all ten brand names within the randomized group assignment. As seen in table 7, results from a
single mediation analysis using responses from the most fluent or most disfluent brand name
presented only showed that fluency was not associated with familiarity (a = 0.456, p = 0.122)
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and familiarity was not associated with the perceived risk of the product (b = 0.093, p = 0.234). A
bias-corrected bootstrap confidence interval for the indirect effect (ab = 0.042) based on 10,000
bootstrap samples was not found to be significant (-0.011, 0.200). Furthermore, there was no
evidence that the fluency of the brand names influenced the perceived risk of the product
independent of the effects of fluency on familiarity (c’ = 0.228, p = 0.305).

Table 7:

Regression Coefficients, Standard Errors, and Model Summary for
Single Mediation Model for Effects of Brand Name Fluency on Perceived
Risk (Sensitivity Analysis with Most Fluent and Disfluent Name)
Familiarity (M)

Variable

Fluency (X)

a

Familiarity (M)
Constant

i1

Perceived Risk (Y)

Coeff.

SE

P

0.456

0.292

0.122

---

---

---

1.565

0.209

<0.001

Coeff.

SE

P

c’

0.228

0.221

0.305

b

0.093

0.078

0.234

i2

3.877

0.198

<0.001

R2 = 0.026

R2 = 0.032

F (1,92) = 2.434, p = 0.122

F (2,91) = 1.485, p = 0.232

Using the same post-hoc variables as analyzed in the single mediation models, we then
assessed the variables in the serial mediation model to determine sensitivity in key study
measures within the full model. First, perceived novelty instead of familiarity was analyzed as
the first mediating variable in the serial mediation model. The first indirect effect assessing the
indirect effect of brand name fluency on willingness to request the product through novelty,
estimated as a1b1, was not found to be significant (a1b1 = 0.515, -0.939, 1.936). The second
indirect effect assessing the effect of brand name fluency on willingness to request the product
through both novelty and perceived risk, estimated as a1d1b2, was also found to not be
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significant (a1d1b2 = 0.205, -0.383, 1.082). Finally, the third indirect effect of brand name
fluency on willingness to request the product through perceived risk, estimated as a2b2 was
found to not be significant (a2b2 = 0.468, -0.861, 4.050). The total indirect effect estimating the
sum of all three indirect effects was determined to not different from zero (1.187, -1.068, 5.465).
The estimated regression coefficients from the serial mediation model are presented in Table 8.
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Regression Coefficients, Standard Errors, and Model Summary for Serial Mediation Model for Effects of
Brand Name Fluency on Willingness to Request (Sensitivity Analysis with Novelty)

Novelty (M1)
Coeff.
Fluency (X)

a1

3.788

Perceived Risk (M2)

95% CI
-0.732, 8.308

Coeff.
a2

0.150

d1

0.150

95% CI
-0.001, 0.302

Novelty (M1)

---

---

Perceived
Risk (M2)

---

---

---

---

Disease
Severity (W)

---

---

---

---

M2 x W

---

---

---

---

Constant

iM1

16.000

12.897, 19.103

R2 = 0.292

F (1,92) = 2.771, p = 0.099

iM2

36.618

Willingness to Request (Y)

-0.001, 0.302

33.230, 40.005

R2 = 0.053
F (2,91) = 2.566, p = 0.082

Coeff.

95% CI

c’

0.853

-4.296, 6.002

b1

0.136

-0.095, 0.367

b2

0.360

-0.537, 1.257

---

---

b3

0.003

-0.004, 0.010

iY

18.695

-18.159, 55.549

R2 = 0.277
F (5,88) = 6.726, p = <0.001
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Table 8:

Next, the three main study variables (fluency, familiarity, and perceived risk) included in
the single mediation analysis were only assessed based on the first pharmaceutical brand name
presented to the participant, as opposed to each participate evaluating all ten brand names within
the randomized group assignment. The first indirect effect assessing the indirect effect of brand
name fluency on willingness to request the product through familiarity, estimated as a1b1, was
not found to be significant (a1b1 = 0.121, -0.049, 0.068). The second indirect effect assessing the
effect of brand name fluency on willingness to request the product through both familiarity and
perceived risk, estimated as a1d1b2, was also found to not be significant (a1d1b2 = 0.007, 0.026, 0.054). Finally, the third indirect effect of brand name fluency on willingness to request
the product through perceived risk, estimated as a2b2 was found to not be significant (a2b2 = 0.004, -0.138, 0.184). The total indirect effect estimating the sum of all three indirect effects was
determined to not different from zero (0.015, -0.143, 0.219). The estimated regression
coefficients from the serial mediation model are presented in Table 9.
Finally, the three main study variables (fluency, familiarity, and perceived risk) were only
assessed for the brand name considered most fluent (i.e., easiest to pronounce) and the brand
name considered the most disfluent (i.e., hardest to pronounce).
The first indirect effect assessing brand name fluency on willingness to request the
product through familiarity, estimated as a1b1, was not found to be significant (a1b1 = 0.063, 0.024, 0.225). The second indirect effect assessing the effect of brand name fluency on
willingness to request the product through both familiarity and perceived risk, estimated as
a1d1b2, was also found to not be significant (a1d1b2 = 0.019, -0.046, 0.081). The third indirect
effect of brand name fluency on willingness to request the product through perceived risk,
estimated as a2b2 was found to not be significant (a2b2 = -0.100, 0.088, 0.501). The total indirect
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was determined to not different from zero (0.182, -0.049, 0.613). The estimated regression
coefficients from the serial mediation model are presented in Table 10.
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Table 9: Regression Coefficients, Standard Errors, and Model Summary for Serial Mediation Model for Effects of Brand
Name Fluency on Willingness to Request (Sensitivity Analysis with First Name)

Coeff.
Fluency (X)

95% CI

0.456

-0.124, 1.036

Familiarity
(M1)

---

---

Perceived Risk
(M2)

---

Disease
Severity (W)
M2 x W
Constant

a1

iM1

Perceived Risk (M2)

Coeff.
a2

95% CI
-0.211, 0.666

Coeff.
c’

95% CI

0.107

-0.439, 0.652

0.093

-0.061, 0.247

b1

0.139

-0.049, 0.327

---

---

---

b2

0.441

-0.338, 1.220

---

---

---

---

---

---

---

---

b3

0.002

-0.004, 0.008

1.565

1.151, 1.980

3.484, 4.268

iY

1.569

-1.682, 4.821

R2 = 0.026

F (1,92) = 2.434, p = 0.122

d1

0.228

Willingness to Request (Y)

iM2

3.876

R2 = 0.032
F (2,91) = 1.484, p = 0.232

---

---

R2 = 0.315
F (5,88) = 8.092, p = <0.001
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Familiarity (M1)

Table 10: Regression Coefficients, Standard Errors, and Model Summary for Serial Mediation Model for Effects of Brand
Name Fluency on Willingness to Request (Sensitivity Analysis with Most Fluent and Disfluent Name)

Coeff.
Fluency (X)

a1

95% CI

0.157

Familiarity
(M1)

Perceived Risk (M2)

-0.195, 0.509
---

Coeff.
a2

---

0.150
d1

0.244

95% CI
-0.001, 0.302

---

---

---

---

Disease
Severity (W)

---

---

---

---

M2 x W

---

---

---

---

16.000

12.897, 19.103

iM1

R2 = 0.008

F (1,92) = 0.782, p = 379

iM2

36.618

Coeff.
c’

-0.014, 0.501

Perceived Risk
(M2)

Constant

Willingness to Request (Y)

33.230, 40.005

R2 = 0.037
F (2,91) = 1.764, p = 0.177

0.244
b1

b2

0.077
0.176
---

b3
iY

0.004
18.695

95% CI
-0.323, 0.811
-0.253, 0.407
-0.473, 0.824
---0.001, 0.010
-18.159, 55.549

R2 = 0.288
F (5,88) = 7.121, p = <0.001
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Familiarity (M1)

CHAPTER V: DISCUSSION

The current research is the first study to our knowledge that demonstrates pharmaceutical
brand name fluency does not affect perceived risk of the product or willingness to request the
medication in actual patients who are evaluating drug names indicated to treat their condition or
disease. In a study among participants with rheumatoid arthritis, we did not find evidence that the
difficulty of pharmaceutical brand names affected evaluations of the product’s perceived risk or
willingness to request the medication from a prescribing physician, even for patients with more
advanced disease. Furthermore, and contrary to most previous fluency theory research with drug
names, the perceived familiarity, or newness of the product, was not associated with the fluency
of the pharmaceutical brand name. Our findings do align with recent research by Dohle and
Montoya (2017) in which the researchers demonstrated that fluent drug names resulted in a
positive as opposed to a negative affective response, which reduced the perceived risks of the
drugs. Dohle and Montoya (2017) also did not find evidence to support the mediating role of
familiarity between the fluency-risk relationship. Additionally, recent work by Bahnik and
Vranka (2017) reported that the relationship between fluency and perceived risk may be much
less robust or even nonexistent. Through a series of experiments, the researchers concluded that
the association between fluency and perceived safety was explained by the length of the name
being evaluated by participants (Bahnik and Vranka 2017). Thus, although findings from the
current study contradict much of the previous fluency theory research involving brand names,
particularly in the context of drug names, recent studies have brought into question the robustness
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and generalizability of the association between processing fluency and judgements of risk.
Two important distinctions between this research and previous fluency theory research
involving drug names are worth noting. First, this is the first study we are aware of that used
study participants who have direct experience with pharmaceuticals in general, and more
specifically, pharmaceuticals indicated to treat a specific condition in which participants are
known to have. Previous fluency theory research involving drug names have not been conducted
with patients in a specific condition or category. This is important difference as actual patients
may be more conditioned to evaluating pharmaceutical brand names and rely upon surrogate
decision makers (i.e., FDA, prescribing physicians) to make trade-off decisions between safety
and efficacy. Research conducted thus far has primarily included students as study participants.
Evaluating brand names, and drug names, from the perspective of a student differs considerably
from that of a patient evaluating the brand names of product indicated to treat a condition for
which the patient has been diagnosed.
Treatment naïve individuals may inherently be more likely to consider risk associated with
a product as a result of less experience with pharmacologic treatments. Experienced patients may
become conditioned through direct experience with pharmacologic therapy and the side effects
associated with treatment. Although Schwarz (2004) demonstrated that the metacognitive
experiences of general consumers are guided by processing fluency, the process may differ in the
context of healthcare. General consumers are much less informed and experienced with drug
therapy and may be more susceptive to the effects of processing fluency for pharmaceutical
products. In fact, Dohle and Siegrist (2014) acknowledged that in a real-world setting, people
actually afflicted by a condition may react differently to heuristic cues such as the complexity of
a brand name.
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Second, contrasting previous research, this study incorporated a between-subjects design
in which participants were randomly assigned to either an easy-to-pronounce group of
pharmaceutical brand names or a hard-to-pronounce group of pharmaceutical brand names.
Extant literature (Song and Schwartz, 2009; Dohle and Siegrist, 2014; Tasso, Gavaruzzi, and
Lotto, 2014; Cho, 2015; Dohle and Montoya, 2017) incorporated within-subjects designs in
studies, exposing participants to both conditions of fluency. Methodological considerations, both
disadvantages and advantages between the two experimental design approaches, have received
considerable attention in the economic and psychology literature (Charness, Uri, and Kuhn,
2012). One particular risk associated with a within-subjects design is a “demand effect”, in which
study participants either consciously or subconsciously attempt to interpret the intentions of the
experiment and change their behavior accordingly (Charness, Uri, and Kuhn, 2012). As a result
of considerations for the strengths and limitations of the two experimental design methods,
between-subject designs have been considered to result in higher external validity in situations in
which an individual is faced with a single decision, which is often the case in evaluations of
whether a patient is willing to request a medication from his/her prescribing physician based on
an advertisement for the medication as evaluated within the current study.
To demonstrate differences in these two methodological approaches, Hayes and Montoya
(2016) recently used the work by Dohle and Siegrist (2014) which, based on fluency theory,
assessed perceived hazardous and willingness to buy drugs based on drug name. In a similar
single mediation model as hypothesized here within the current research, Dohle and Siegrist
(2014) assumed the effects of drug name fluency (i.e., complexity) would be mediated on
willingness to buy through participants perceived hazardousness. Hayes and Montoya (2016)
applied a hypothetical between-subjects approach to the Dohle and Siegrist (2014) data and found
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that complex sounding names were considered to be more hazardous than drugs with simpler
names (t [42] = 2.618, p = 0.012, 95% CI [0.183,1.417]) which negatively affected willingness to
buy through hazardousness (Hayes and Montoya, 2016). However, the mediation analysis
conducted by Dohle and Siegrist (2014) using the within-subjects design found no statistically
significant difference in willingness

to buy based on drug name but instead, concluded a full or

complete mediation effect, indicating that differences in hazardousness predicts willingness to
buy (Hayes and Montoya, 2016). Disparate results from previous fluency theory research found
within the current study may partially be the result of methodological advantages of the betweensubjects design incorporated in this study.

Limitations
There are limitations associated with this research that should be recognized. Participants
evaluated hypothetical brand names of products indicated to treat RA. Patients self- identified as
having been previously diagnosed with RA and therefore a confirmed diagnosis was not obtained
for study participants. Although the survey captured participants’ experience with various forms
of RA treatment and their measure of disease severity, it is possible that participants did not have
a confirmed clinical diagnosis of RA and therefore may not be suited to evaluate hypothetical
products indicated to treat RA. Additionally, although the study incorporated a between-subjects
designs, participants in each fluency group were exposed to a total of 10 brand names and could
have experienced response burden or responder fatigue as a result. A sensitivity analysis was
conducted to address this limitation by only analyzing the first brand name presented to each
respondent. Finally, although this study attempts to investigate the fluency risk connection in a
real-world setting with patients, the findings may not translate to other conditions outside of RA.
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Patients with conditions that differ in symptoms, criticality, and even prevalence from that of RA
may respond dissimilarly when evaluating brand names indicated to treat their disease.

Implications
The current study has implications for both the growing body of fluency theory research
and pharmaceutical industry itself. First, this study provides additional evidence as to the
potential limitations in the previously established link between processing fluency and
judgements such as perceived risk. Although the original work by Song and Schwartz (2009) has
been replicated in subsequent studies, recent work by Dohle and Siegrist (2014), Bahnik and
Vranka (2017), and the current study have demonstrated conflicting results

to the relationships

between processing fluency and judgements associated with disfluent brand names.
Future research should explore these possible boundary conditions and assess the
robustness and generalizability of the fluency risk relationship. From an industry perspective, the
results are supportive of recent naming trends and indicate that the complexity of pharmaceutical
brand names do not negatively influence patients’ willingness to act to advertising initiatives and
request a medication from their healthcare provider. As the pharmaceutical market in the US
continues to grow, with forty-six new products introduced in 2017 alone, pharmaceutical
marketing practitioners should further investigate other judgements such as perceived efficacy
and value that may be influenced by the complexity of the brand name.
Additionally, it is important to understand the potential impact of the fluency risk
relationship on prescribing practitioners. Physicians and health care providers act as surrogate
consumers for patients in the US health care market by choosing medications to prescribe for a
patient. Determining what effect, if any, the fluency of pharmaceutical brand names on
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prescribing practitioners is needed to further expand the real-world impact of processing fluency
in the context of pharmaceuticals.

Conclusion
In conclusion, the present study suggests that ease of pronunciation of a pharmaceutical
brand name does not affect patients perceived risk associated with the product or their willingness
to request the medication from their healthcare provider. This research contributes to the fluency
theory literature and provides a unique perspective on the real- world implications, or lack
thereof, of brand name selection for pharmaceutical products.
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Appendix A: Pre-test Instructions

Thank you for your willingness to participate in this study. Your input is very valuable to the research team.
Throughout this process, you will see a series of 45 brand names of pharmaceutical products. We are interested in
how easy, or difficult, each of the brand names are to pronounce. The following scale will be used so that you can
rate each brand name based on ease of pronunciation. You will have a chance to rate each individual brand name
before going to the next product.
NOTE: Each numerical value will have a check box function to allow participants to select (or click) the appropriate
number.
Please rate the following pharmaceutical brand names how easy the names are to pronounce.

1

2

3

4

5

Placed directly above each numerical value will be the following labels:
1 = Very difficult to pronounce
2 = Moderately difficult to pronounce 3 =
Slightly difficult to pronounce
4 = Neither easy nor difficult to pronounce 5 =
Slightly easy to pronounce
6 = Moderately easy to pronounce 7 = Very
easy to pronounce
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6

7

Appendix B: Example Study Measure Format

Imagine you see the following pharmaceutical product name and
accompanying information during an advertisement for the product.

Rotipix
Rotipix is a pharmaceutical product
that is indicated for the treatment of
Rheumatoid Arthritis
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Perceived Familiarity
How would you rate the novelty of the product brand name listed above?

1

2

3

4

5

6

7

6

7

Placed directly above each numerical value will be the following labels: 1 = Very old
2 = Moderately old 3 =
Slightly old
4 = Neither old nor new 5 =
Slightly new
6 = Moderately new 7 =
Very new

Perceived Risk Measure
How well do you expect the product listed above will perform?

1

2

3

4

5

Placed directly above each numerical value will be the following labels: 1 = Extremely
poor
2 = Moderately poor 3 =
Slightly poor
4 = Neither poor nor good 5 =
Slightly good
6 = Moderately good 7 =
Extremely good
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Perceived Risk Measure
How concerned would you be about using the product listed above?

1

2

3

4

5

6

7

6

7

Placed directly above each numerical value will be the following labels: 1 = Consider the
product very harmful
2 = Consider the product moderately harmful 3 =
Consider the product slightly harmful
4 = Consider the product neither safe nor harmful 5 = Consider
the product slightly safe
6 = Consider the product moderately safe 7 =
Consider the product very safe

Willingness to Request
1

2

3

4

5

Placed directly above each numerical value will be the following labels: 1 = Very
unlikely
2 = Somewhat unlikely 3 =
Unlikely
4 = Neither unlikely nor likely 5 =
Likely
6 = Somewhat likely 7 =
Very likely
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Appendix C: Survey

Q1 Investigator Contact
David Wamble
The University of Mississippi School of Pharmacy dewamble@go.olemiss.edu

In this survey, you will be presented with a series of brand names for prescription pharmaceutical products
indicated to treat rheumatoid arthritis. Once each product name is presented, you will be asked to respond to a few
questions. Please select the most appropriate answer which best describes your impression of the pharmaceutical
brand name.

The survey will require approximately 10-15 minutes to complete. Participation is strictly voluntary and you may
refuse to participate at any time.
This study has been reviewed by The University of Mississippi’s Institutional Review Board (IRB). If you have
any questions, concerns, or reports regarding your rights as a participant of research, please contact the IRB at
(662) 915-7482 or irb@olemiss.edu.

Statement of Consent
I have read the procedure described above. Clicking the "Proceed" button below signifies that I voluntarily agree to
participate in the survey.

o
o

Proceed

Do not proceed

Q2 What is your age in years?
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Q3 Have you ever been diagnosed with rheumatoid arthritis?

o
o

Yes

No
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Q4 How long ago were you diagnosed with rheumatoid arthritis?

o

Less than 1 year ago

o

1 to 3 years ago

o

3 to 7 years ago

o

More than 7 years ago

o

Not sure

Q5 What is your gender?

o
o

Male

Female

Q6 Please specify your ethnicity

o
o

White

Hispanic or Latino
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o

Black or African American

o

Native American or American Indian

o

Asian/Pacific Islander

o

Other

75

Q7 Are you a native English (US) speaker?

o
o

Yes

No

Q8 What is the highest degree or level of school you have completed?

o

High School or diploma equivalent (for example: GED)

o

o
o
o
o

Associate degree

Bachelor's degree

Master's degree

Professional degree
Doctorate degree

Q9 Do you work in a healthcare related field or for a healthcare organization?

o
o

Yes

No

Q10 Approximately how many prescription medications are you currently taking?

o
o

None
1 - 3 prescriptions
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o

4 - 6 prescriptions

o

More than 6 prescriptions

77

Q11 Approximately how many prescription medications are you currently taking for rheumatoid arthritis?

o
o
o
o

None
1
2
3 or more

Q12 Are the medications you are currently taking for rheumatoid arthritis injected/infused or taken by mouth?

o

Injected/Infused

o
o

Oral
Both injected/infused and oral

o

Not sure

Q13 How much pain have you had because of your rheumatoid arthritis IN THE PAST WEEK? On a scale of 0 to
100 (where zero represents “no pain” and 100 represents “severe pain”), please slide the bar to record the number
below.
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No pain

Severe pain

0

100
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Q14 Considering all the ways that your arthritis affects you, please rate how well you are doing on a scale from 0 to
100 (where zero represents “very well” and 100 represents “very poor” health). Please slide the bar to record the
number below.
Very well

0

Very poor

100

Q15 You will now be presented with a series of brand names of prescription pharmaceutical products indicated to
treat rheumatoid arthritis. Once each product name is presented, you will be asked to respond to a few questions.
Please select the most appropriate answer which best describes your impression of the pharmaceutical brand name.

Q16
Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Evafir

Evafir is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid
Arthritis
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Q17 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar
Q18 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old

o

Slightly old

o

Neither old nor new
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o

Slightly new

Moderately new

o
o

Very new

82

Q19 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

Q20 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely
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o

Somewhat unlikely

o

Neither unlikely nor likely

o

Somewhat likely

o

Likely

o

Very likely
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Q21
Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Solotho

Solotho is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid
Arthritis

Q22 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar
Q23 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old
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o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new

86

Q24 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

Q25 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely
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o

Somewhat unlikely

o

Neither unlikely nor likely

o

Somewhat likely

o
o

Likely
Very likely Q26

Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Trivete

Trivete is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis

88

Q27 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar
Q28 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old

o

Slightly old

o

Neither old nor new
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o

Slightly new

Moderately new

o
o

Very new

90

Q29 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

Q30 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely
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o

Somewhat unlikely

o

Neither unlikely nor likely

o

Somewhat likely

o

Likely

o

Very likely
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Q31
Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Solatu

Solatu is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis

Q32 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar
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Q33 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old

o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new
Q34 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful
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o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe
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Q35 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely

o

Neither unlikely nor likely

o

Somewhat likely

o
o

Likely
Very likely Q36

Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Vithoria

Vithoria is a prescription pharmaceutical product that is indicated for the treatment of
Rheumatoid Arthritis
Q37 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar
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o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very

familiar
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Q38 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old

o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new

Q39 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe
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o

Consider the product moderately safe

o

Consider the product very safe

Q40 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely
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o

Neither unlikely nor likely

o

Somewhat likely

o
o

Likely
Very likely Q41

Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Runfina

Runfina is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid
Arthritis

Q42 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o
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Very familiar

101

Q43 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old

o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new
Q44 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful
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o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe
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Q45 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely

o

Neither unlikely nor likely

o

Somewhat likely

o
o

Likely
Very likely Q46

Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Cutrino

Cutrino is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis

Q47 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar
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o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very

familiar
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Q48 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old

o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new
Q49 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful
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o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe
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Q50 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely

o

Neither unlikely nor likely

o

Somewhat likely

o
o

Likely
Very likely Q51

Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Altorex

Altorex is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis
Q52 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar
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o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very

familiar
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Q53 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old

o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new
Q54 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful
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o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

111

Q55 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely

o

Neither unlikely nor likely

o

Somewhat likely

o
o

Likely
Very likely

Q56
Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Naxalon

Naxalon is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis

Q57 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar
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o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar

113

Q58 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old

o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new

114

Q59 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

Q60 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely
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o

Neither unlikely nor likely

o

Somewhat likely

o

Likely

o

Very likely
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Q61
Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Velcin

Velcin is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis

Q62 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar
Q63 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old
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o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new

118

Q64 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

Q65 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely
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o

Neither unlikely nor likely

o

Somewhat likely

o
o

Likely
Very likely Q66

You are now going to see a series of pharmaceutical brand names. Please take a moment to pronounce each name,
saying the name aloud or to yourself. You will then be asked to rate each pharmaceutical brand name based on how
easy the name is to pronounce. Please make sure to rate each of the brand names before proceeding to the next.
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Q67 Please rate the following pharmaceutical brand name based on how easy the name is to
pronounce.
Very
difficult to
pronounce

Evafir

Moderately
difficult to
pronounce

o

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

o

pronounce

o

o

Slightly
easy to
pronounce

Moderately
easy to
pronounce

o

Very easy
to
pronounce

o

o

Q68 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

Solotho

Q69 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

Trivete

Q70 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

Solatu
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Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

Q71 Please rate the following pharmaceutical brand name based on how easy the name is to
pronounce.
Very
difficult to
pronounce

Vithoria

Moderately
difficult to
pronounce

o

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

o

pronounce

o

o

Slightly
easy to
pronounce

Moderately
easy to
pronounce

o

Very easy
to
pronounce

o

o

Q72 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

Runfina

Q73 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

Cutrino

Q74 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

Altorex
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Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

Q75 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

Naxalon

Q76 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

Velcin

Q137 Thank you for your participation! Please provide your name and email below so payment can be processed for
taking part in this study.

Q77
Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Niyxob

Niyxob is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis
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Q78 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar
Q79 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old

o

Slightly old

o

Neither old nor new
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o

Slightly new

Moderately new

o
o

Very new

125

Q80 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

Q81 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely
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o

Neither unlikely nor likely

o

Somewhat likely

o

Likely

o

Very likely

127

Q82
Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Quthutix

Quthutix is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid
Arthritis
Q83 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar
Q84 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old
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o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new

129

Q85 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

Q86 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely
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o

Neither unlikely nor likely

o

Somewhat likely

o

Likely

o

Very likely

131

Q87
Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Oxgnue

Oxgnue is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid
Arthritis
Q88 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar
Q89 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old
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o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new

133

Q90 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

Q91 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely
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o

Neither unlikely nor likely

o

Somewhat likely

o

Likely

o

Very likely

135

Q92
Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Enyvfo

Enyvfo is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis

Q93 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar
Q94 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old
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o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new

137

Q95 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

Q96 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely
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o

Neither unlikely nor likely

o

Somewhat likely

o

Likely

o

Very likely

139

Q97
Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Vetlixfi

Vetlixfi is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis
Q98 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar
Q99 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old
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o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new

141

Q100 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

Q101 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely
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o

Neither unlikely nor likely

o

Somewhat likely

o

Likely

o

Very likely

143

Q102
Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Subridke

Subridke is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid
Arthritis
Q103 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar
Q104 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old
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o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new

145

Q105 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

Q106 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely
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o

Neither unlikely nor likely

o

Somewhat likely

o
o

Likely
Very likely Q107

Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Oxibinle

Oxibinle is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid
Arthritis
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Q108 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar
Q109 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old

o

Slightly old

o

Neither old nor new
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o

Slightly new

Moderately new

o
o

Very new

149

Q110 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

Q111 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely
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o

Neither unlikely nor likely

o

Somewhat likely

o

Likely

o

Very likely

151

Q112
Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Oxtieze

Oxtieze is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid
Arthritis

Q113 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar
Q114 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old
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o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new

153

Q115 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

Q116 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely
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o

Neither unlikely nor likely

o

Somewhat likely

o

Likely

o

Very likely
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Q117
Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Asbixat

Asbixat is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid
Arthritis
Q118 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar
Q119 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old
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o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new

157

Q120 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

Q121 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

o

Somewhat unlikely
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o

Neither unlikely nor likely

o

Somewhat likely

o

Likely

o

Very likely
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Q122
Imagine you see the following prescription pharmaceutical product name and accompanying information during an
advertisement for the product

Docilge

Docilge is a prescription pharmaceutical product that is indicated for the treatment of Rheumatoid Arthritis

Q123 How familiar to you is the prescription pharmaceutical product listed above?

o

Very unfamiliar

o

Moderately unfamiliar

o

Slightly unfamiliar

o

Neither familiar nor unfamiliar

o

Slightly familiar

Moderately familiar

o
o

Very familiar
Q124 How would you rate the novelty of the prescription pharmaceutical product listed above?

o

Very old

o

Moderately old
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o

Slightly old

o

Neither old nor new

o

Slightly new

Moderately new

o
o

Very new

161

Q125 How concerned would you be about using the prescription pharmaceutical product listed above?

o

Consider the product very harmful

o

Consider the product moderately harmful

o

Consider the product slightly harmful

o

Consider the product neither safe nor harmful

o

Consider the product slightly safe

o

Consider the product moderately safe

o

Consider the product very safe

Q126 How willing would you be to request the prescription pharmaceutical product from your physician?

o

Very unlikely

o

Unlikely

Niyxob
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o

Somewhat unlikely

o

Neither unlikely nor likely

o

Somewhat likely

o

Likely

o

Very likely

Q127 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce
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Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

Q128 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

Quthutix

Q129 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

Oxgnue

Q130 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

Enyvfo

Q131 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

Vetlixfi
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Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

The Role of Brand Name Fluency: A Pharmaceutical Marketing Perspective

Q132 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.
Very
difficult to
pronounce

Subridke

Moderately
difficult to
pronounce

o

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

o

pronounce

o

o

Slightly
easy to
pronounce

Moderately
easy to
pronounce

o

Very easy
to
pronounce

o

o

Q133 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

Oxibinle

Q134 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

Oxtieze

Q135 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.

Very
difficult to
pronounce

Moderately
difficult to
pronounce

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

Asbixat
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Slightly
easy to
pronounce

Moderately
easy to
pronounce

Very easy
to
pronounce

Q136 Please rate the following pharmaceutical brand name based on how easy the name is to pronounce.
Very
difficult to
pronounce

Docilge

o

Moderately
difficult to
pronounce

o

Neit her
easy nor
difficult to

Slightly
difficult to
pronounce

pronounce

o

o
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Slightly
easy to
pronounce

o

Moderately
easy to
pronounce

o

Very easy
to
pronounce

o
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